New medicinal use of nintedanib, and derivative and medicinal salt thereof

Abstract

The invention relates to new medicinal use of nintedanib, and a derivative and a medicinal salt thereof, in particular to the use in preparing a medicine for preventing and / or treating peritoneal adhesion. Animal experiment results show that the nintedanib can significantly reduce the occurrence of the peritoneal adhesion after abdominal surgery of rats, improve the texture of the peritoneal adhesion, reduce the toughness of the peritoneal adhesion, and reduce an inflammation and fibrosis degree of peritoneal tissues. An important theoretical basis for the use of the nintedanib, and the derivative or the medicinal salt thereof in treating peritoneal adhesion is provided, a treatment range of the medicine is widened, and meanwhile a new medicine solution for treating the peritoneal adhesion is provided.

Description

technical field

[0001] The invention belongs to the technical field of pharmaceutical application, and specifically relates to the new application of nintedanib, its derivatives or pharmaceutically acceptable salts. Background technique

[0002] Peritoneal adhesion is a common complication of abdominal and pelvic surgery, and its incidence rate can be as high as 90%. It is an important problem that has plagued the field of clinical diagnosis and treatment for a long time. Peritoneal adhesions can lead to many serious complications, including intestinal obstruction, infertility, chronic abdominal and pelvic pain, etc., which seriously affect the health and quality of life of patients. More than 20% of patients with peritoneal adhesions will need to be re-admitted to the hospital for adhesiolysis and other treatments due to symptoms such as intestinal obstruction, but the recurrence rate of peritoneal adhesions after surgery is still high, which not only increases the burden o...

Images